| Literature DB >> 23173023 |
Marina V Atzingen1, Mônica L Vieira, Rosane Oliveira, Renan F Domingos, Renata S Mendes, Aline T Barros, Amane P Gonçales, Zenaide M de Morais, Silvio A Vasconcellos, Ana Lto Nascimento.
Abstract
Leptospirosis is a worldwide zoonosis caused by pathogenic Leptospira. The whole-genome sequence of L. interrogans serovar Copenhageni together with bioinformatics tools represent a great opportunity to search for novel antigen candidates that could be used as subunit vaccine against leptospirosis. We focused on six genes encoding for conserved hypothetical proteins predicted to be exported to the outer membrane. The genes were amplified by PCR from Leptospira interrogans genomic DNA and were cloned and expressed in Escherichia coli. The recombinant proteins tagged with N-terminal hexahistidine were purified by metal-charged chromatography. The immunization of hamsters followed by challenge with lethal dose of virulent strain of Leptospira showed that the recombinant proteins Lsa21, Lsa66 and rLIC11030 elicited partial protection to animals. These proteins could be used combined or in a mixture with novel adjuvants in order to improve their effectiveness.Entities:
Keywords: Leptospira interrogans; leptospirosis; recombinant protein; vaccine.
Year: 2012 PMID: 23173023 PMCID: PMC3502890 DOI: 10.2174/1874285801206010079
Source DB: PubMed Journal: Open Microbiol J ISSN: 1874-2858
Fig. (4)Survival curves of hamsters immunized with recombinant proteins and challenged with virulent leptospires. The animals were immunized subcutaneously with PBS (negative control), bacterin (killed whole-leptospires) (positive control), Lsa21, Lsa66, rLIC11030, rLIC10821, Lsa25 or rLIC10672. Two weeks after the second immunization (day 30) with the recombinant proteins, the animals were challenged intraperitoneally with 3 - 5 X 107 of L. interrogans serovar Kennewicki strain Pomona Fromm (LPF) in PBS. The animals were monitored for morbidity until day 21 post-challenge. A and B depicted the data of two independent experiments.
Gene Locus, Protein name, NCBI Reference Sequence, Features, Gene Conservation, Sequence of the Primers Employed for DNA Amplification, and Molecular Mass of Expressed Recombinant Proteins
| Gene Locus | Recombinant Protein given Name | NCBI Reference Sequence Number | Description/Function | Conservation (Identity) | Sequence of primers for PCR amplification | Recombinant Protein Molecular Mass |
|---|---|---|---|---|---|---|
| LIC10368 | Lsa21 | YP_000355 | Putative lipoprotein | Lai (100 %) | F: 5´ CACCGATGAAAAAAAAGAAAATGAATTGAG 3’ | 21 kDa |
| LIC10258 | Lsa66 | YP_000249 | Hypothetical protein with ompA domain | Lai (99 %) | F:5´ | 65 kDa |
| LIC11030 | rLIC11030 | YP_001000 | Putative lipoprotein with a domain of unknown function (DUF1565) | Lai (99 %) | F: 5` | 37 kDa |
| LIC10821 | rLIC10821 | YP_000798 | Putative lipoprotein with a domain of unknown function (DUF1565) | Lai (100 %) | F: 5´ | 37 kDa |
| LIC12253 | Lsa25 | YP_002188 | Putative lipoprotein with a domain of unknown function (DUF1566) | Lai (100 %) | F: 5´ | 24 kDa |
| LIC10672 | rLIC10672 | YP_000656 | hypothetical protein | Lai (100 %) | F: 5´CC | 23 kDa |
http://aeg.lbi.ic.unicamp.br/world/lic/ [30, 41].
http://www.ncbi.nlm.nih.gov/protein/.
Protein BLAST - http://www.ncbi.nlm.nih.gov/blast/Blast.cgi [42, 43].
Previously published by Oliveira et al [26].
Previously published by Atzingen et al [24]
Previously published by Mendes et al [25]
Previously published by Felix et al. [21]; Domingos et al., [27].
Lai: L. interrogans serovar Lai [44]; LBH: L. borgpetersenii serovar Hardjo-bovis [45]; LBP: L. biflexa serovar Patoc [46].
Protective Efficacy of Recombinant Proteins in a Hamster Model
| Antigen | Experiment 1 | Experiment 2 | ||||
|---|---|---|---|---|---|---|
| % Protection (No. Surviving/Total) | Culture (Negative/Total) | % Protection (No. Surviving/Total) | Culture (Negative/Total) | |||
| killed whole-leptospires | 100 % (10/10) | <0.0001 | 10/10 | 100 % (10/10) | 0.0002 | 10/10 |
| PBS | 0 % (0/10) | -------- | ND | 20 % (2/10) | -------- | 2/2 |
| Lsa21 | 30 % (3/10) | 0.0470 | 1/3 | 20 % (2/10) | 0.9224 | 2/2 |
| Lsa66 | 20 % (2/10) | 0.0092 | 1/2 | 30 % (3/10) | 0.6768 | 1/3 |
| rLIC11030 | 30 % (3/10) | 0.0144 | 2/3 | 30 % (3/10) | 0.5102 | 2/3 |
| rLIC10821 | 20 % (2/10) | 0.0640 | 2/2 | 20 % (2/10) | 0.8628 | 1/2 |
| Lsa25 | 20 % (2/10) | 0.0640 | 1/2 | 30 % (3/10) | 0.3784 | 3/3 |
| rLIC10672 | 0 % (0/10) | 0.4180 | ND | 40 % (4/10) | 0.3393 | 4/4 |
The statistical analysis was performed by Kaplan-Meier method [40] and Logrank test compared to PBS survival curves.
P-values (< 0.05) considered to indicate statistical significance.
ND: not determined